116 related articles for article (PubMed ID: 4906641)
1. On the modification of paranoid symptomatology. II. Stylistic considerations and the effectiveness of phenothiazines.
Freedman N; Cutler R; Engelhardt DM; Margolis R
J Nerv Ment Dis; 1970 Jan; 150(1):68-76. PubMed ID: 4906641
[No Abstract] [Full Text] [Related]
2. On the modification of paranoid symptomatology.
Freedman N; Cutler R; Engelhardt DM; Margolis R
J Nerv Ment Dis; 1967 Jan; 144(1):29-36. PubMed ID: 5337100
[No Abstract] [Full Text] [Related]
3. The hospitalization proneness scale as a predictor of response to phenothiazine treatment. II. Delay of psychiatric hospitalization.
Rosen B; Engelhart DM; Freedman N; Margolis R; Klein DF
J Nerv Ment Dis; 1971 Jun; 152(6):405-11. PubMed ID: 4935067
[No Abstract] [Full Text] [Related]
4. The differential response to parenteral chlorpromazine and mesoridazine in psychotic patients.
Brauzer B; Goldstein BJ
J Clin Pharmacol J New Drugs; 1970; 10(2):126-31. PubMed ID: 4906541
[No Abstract] [Full Text] [Related]
5. Physician bias and the double-blind.
Engelhardt DM; Margolis RA; Rudorfer L; Paley HM
Arch Gen Psychiatry; 1969 Mar; 20(3):315-20. PubMed ID: 4884940
[No Abstract] [Full Text] [Related]
6. Phenothiazines in prevention of psychiatric hospitalization. IV. Delay or prevention of hospitalization--a reevaluation.
Engelhardt DM; Rosen B; Freedman N; Margolis R
Arch Gen Psychiatry; 1967 Jan; 16(1):98-101. PubMed ID: 5333777
[No Abstract] [Full Text] [Related]
7. Differences in clinical effects of three phenothiazines in "acute" schizophrenia.
Dis Nerv Syst; 1967 Jun; 28(6):369-83. PubMed ID: 5342391
[No Abstract] [Full Text] [Related]
8. COMMUNICATION OF BODY COMPLAINTS AND PARANOID SYMPTOM CHANGE UNDER CONDITIONS OF PHENOTHIAZINE TREATMENT.
FREEDMAN N; ENGELHARDT D; MANN D; MARGOLIS R; LONDON S
J Pers Soc Psychol; 1965 Apr; 1():310-8. PubMed ID: 14328737
[No Abstract] [Full Text] [Related]
9. Clinical evaluation of pipotiazine palmitate (19.552 R.P.) used on patients in an acute reception ward.
Elley JH; Petersen JH
Acta Psychiatr Scand Suppl; 1973; 241():75-82. PubMed ID: 4147514
[No Abstract] [Full Text] [Related]
10. Family interaction patterns, drug treatment, and change in social aggression.
Cohen M; Freedman N; Engelhardt DM; Margolis RA
Arch Gen Psychiatry; 1968 Jul; 19(1):50-6. PubMed ID: 5661009
[No Abstract] [Full Text] [Related]
11. The hospitalization proneness scale as a predictor of response to phenothiazine treatment.
Rosen B; Engelhardt DM; Freedman N; Margolis R
J Nerv Ment Dis; 1968 Jun; 146(6):476-80. PubMed ID: 5677025
[No Abstract] [Full Text] [Related]
12. [Results of treatment of schizophrenic psychoses with neuroleptics combined with subcomatic insulin].
Majewski J; Stempurska K
Psychiatr Pol; 1968; 2(1):37-42. PubMed ID: 4875961
[No Abstract] [Full Text] [Related]
13. Acute paranoid schizophrenia. (Treatment with chlorpromazine, trifluoperazine and placebo).
Reardon JD; Abrams S
Dis Nerv Syst; 1966 Apr; 27(4):265-70. PubMed ID: 5936140
[No Abstract] [Full Text] [Related]
14. Paranoid and withdrawal symptoms in schizophrenia: differential symptom reduction over time.
Goldberg SC; Schooler NR; Mattsson N
J Nerv Ment Dis; 1967 Aug; 145(2):158-62. PubMed ID: 4861752
[No Abstract] [Full Text] [Related]
15. Specific indications for different classes of phenothiazines.
Hollister LE; Overall JE; Kimbell I; Pokorny A
Arch Gen Psychiatry; 1974 Jan; 30(1):94-9. PubMed ID: 4148660
[No Abstract] [Full Text] [Related]
16. Premorbid asocial adjustment and response to phenothiazine treatment among schizophrenic inpatients.
Klein DF; Rosen B
Arch Gen Psychiatry; 1973 Oct; 29(4):480-5. PubMed ID: 4583948
[No Abstract] [Full Text] [Related]
17. Clinical experience with pipotiazine palmitate (19.552 R.P.) in Nordic countries. Report of a multicentre investigation.
Kristjansen P; Dencker SJ; Elley J; Hakola A; Heshe J; Malm U; Robak OH; Salvesen C; Vaksdal K
Acta Psychiatr Scand Suppl; 1973; 241():51-6. PubMed ID: 4147511
[No Abstract] [Full Text] [Related]
18. Treatment of paranoid schizophrenics with chlorpromazine and group therapy.
Borowski T; Tolwinski T
Dis Nerv Syst; 1969 Mar; 30(3):201-2. PubMed ID: 5774344
[No Abstract] [Full Text] [Related]
19. Correlation between plasma chlorpromazine and its metabolites and clinical ratings in patients with acute relapse of schizophrenic and paranoid psychosis.
Phillipson OT; McKeown JM; Baker J; Healey AF
Br J Psychiatry; 1977 Aug; 131():172-84. PubMed ID: 912219
[TBL] [Abstract][Full Text] [Related]
20. [Importance of trifluoperazine in the process of social readaptation in cases of chronic schizophrenia].
Cieślik Z; Leczycka K; Thille Z; Trembla K
Psychiatr Pol; 1969; 3(3):333-9. PubMed ID: 4896422
[No Abstract] [Full Text] [Related]
[Next] [New Search]
